A Lentivirus Vaccine for HIV

HIV 慢病毒疫苗

基本信息

  • 批准号:
    6409274
  • 负责人:
  • 金额:
    $ 26.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-09-01 至 2003-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Provided by applicant): Recent research has made it clear that the development of a successful HIV vaccine will depend on the choice of target antigen(s), the ability to induce appropriate immune responses to these antigens through the use of a suitable delivery system, and whether the virus is able to escape these immune responses by genetic adaptations. The induction of cellular-based immune responses, most notably CTL, to multiple and conserved viral antigens appears central to addressing these issues. Consistent with this is the observation that attenuated virus vaccination can successfully protect non-human primates. An "attenuated" HIV vaccine will be developed by incorporating a completely safe, disabled HIV immunogen (HIVgag/pol/tatnf/rev) in a non-human lentiviral system (Lenti-HIV) based on the feline immunodeficiency virus. This vaccine will not only safely mimic HIV infection, but will present a broad number of safe viral genes. Also, this vaccine will be administered via a mucosal route to optimally induce mucosal specific immune responses. This approach will allow the immune system to generate a broad cellular based immune response at the portals of HIV infection. In addition, due to the large insert capacity of lentiviral vectors, this vaccine platform offers the flexibility to include immune enhancing cytokines to ensure the development of appropriate immune responses. Studies to be conducted analyzing the efficacy of Lenti-HIV include i) transduction analysis of relevant target cells and organs, ii) expression levels and duration of the immunogen, iii) cellular immune responses to HIV induced in vitro and in vivo, and iv) protection against mucosal infection in a small animal model.
描述(由申请人提供):最近的研究表明,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sybille L Sauter其他文献

Sybille L Sauter的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sybille L Sauter', 18)}}的其他基金

Non-Integrating FIV Vectors for HIV Vaccines
用于 HIV 疫苗的非整合 FIV 载体
  • 批准号:
    7123310
  • 财政年份:
    2006
  • 资助金额:
    $ 26.25万
  • 项目类别:
FIV Vectors for the Treatment of Hemophilia A
用于治疗 A 型血友病的 FIV 载体
  • 批准号:
    6992338
  • 财政年份:
    2005
  • 资助金额:
    $ 26.25万
  • 项目类别:
A Lentivirus Vaccine for HIV
HIV 慢病毒疫苗
  • 批准号:
    6746111
  • 财政年份:
    2004
  • 资助金额:
    $ 26.25万
  • 项目类别:
Lentiviral Vector Gene Therapy for CD45 Deliver
CD45 慢病毒载体基因治疗
  • 批准号:
    6645847
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Lentiviral Vector Gene Therapy for CD45 Deliver
CD45 慢病毒载体基因治疗
  • 批准号:
    6751633
  • 财政年份:
    2003
  • 资助金额:
    $ 26.25万
  • 项目类别:
Non-Primate FIV Vectors for Treatment of Hemophilia A
用于治疗甲型血友病的非灵长类 FIV 载体
  • 批准号:
    6444339
  • 财政年份:
    2002
  • 资助金额:
    $ 26.25万
  • 项目类别:
A Max-Ad Vaccine for Mucosal Immunity to HIV
一种针对 HIV 粘膜免疫的 Max-Ad 疫苗
  • 批准号:
    6511633
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:
A Max-Ad Vaccine for Mucosal Immunity to HIV
一种针对 HIV 粘膜免疫的 Max-Ad 疫苗
  • 批准号:
    6402992
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:
A Lentivirus Vaccine for HIV
HIV 慢病毒疫苗
  • 批准号:
    6534363
  • 财政年份:
    2001
  • 资助金额:
    $ 26.25万
  • 项目类别:

相似国自然基金

Lentivirus载体转染骨髓间质干细胞诱导增殖和成骨细胞定向分化修复骨缺损的研究
  • 批准号:
    30371434
  • 批准年份:
    2003
  • 资助金额:
    20.0 万元
  • 项目类别:
    面上项目

相似海外基金

Lentivirus Construct Core
慢病毒构建核心
  • 批准号:
    10630391
  • 财政年份:
    2023
  • 资助金额:
    $ 26.25万
  • 项目类别:
Lentivirus Rev protein: characterization and study of Rev - nucleolar protein interactions
慢病毒 Rev 蛋白:Rev - 核仁蛋白相互作用的表征和研究
  • 批准号:
    RGPIN-2016-06532
  • 财政年份:
    2022
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Discovery Grants Program - Individual
Improving the production and quality of lentivirus for the transduction of haematopoeitic stem cells via a perfusion culture process
通过灌注培养过程提高用于转导造血干细胞的慢病毒的产量和质量
  • 批准号:
    2734111
  • 财政年份:
    2022
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Studentship
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure
慢病毒样颗粒将 Cas12 核糖核蛋白 (RNP) 特异性递送至体内 HIV 储存细胞以治疗 HIV
  • 批准号:
    10598912
  • 财政年份:
    2022
  • 资助金额:
    $ 26.25万
  • 项目类别:
Improving the production and quality of lentivirus for the transduction of haematopoeitic stem cells via a perfusion culture process
通过灌注培养过程提高用于转导造血干细胞的慢病毒的产量和质量
  • 批准号:
    2585771
  • 财政年份:
    2021
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Studentship
Lentivirus Rev protein: characterization and study of Rev - nucleolar protein interactions
慢病毒 Rev 蛋白:Rev - 核仁蛋白相互作用的表征和研究
  • 批准号:
    RGPIN-2016-06532
  • 财政年份:
    2020
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Discovery Grants Program - Individual
Repertoire-scale T cell antigen identification via peptide-MHC lentivirus display
通过肽-MHC 慢病毒展示进行全库规模 T 细胞抗原鉴定
  • 批准号:
    10001123
  • 财政年份:
    2020
  • 资助金额:
    $ 26.25万
  • 项目类别:
Lentivirus persistence in the brain: viral, host and therapeutic determinants
慢病毒在大脑中的持久性:病毒、宿主和治疗决定因素
  • 批准号:
    401955
  • 财政年份:
    2019
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Operating Grants
Development of a scalable and consistent process for the production of lentivirus for gene-modified cell therapies
开发用于基因修饰细胞疗法的慢病毒生产的可扩展且一致的工艺
  • 批准号:
    2246819
  • 财政年份:
    2019
  • 资助金额:
    $ 26.25万
  • 项目类别:
    Studentship
Lentivirus Replication Strategy and Pathogenesis
慢病毒复制策略和发病机制
  • 批准号:
    10700321
  • 财政年份:
    2018
  • 资助金额:
    $ 26.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了